<p>Belpointe Asset Management LLC 在最近向证券交易委员会提交的文件中表示，在第三季度减少了对艾尔利公司（NYSE:LLY - 免费报告）17.0% 的持股。这家机构投资者在该期间出售了 964 股后，持有该公司 4,707 股股票。Belpointe Asset Management LLC 在艾尔利公司的持股在最近一个季度末价值为 3,592,000 美元。</p>
<p>获取 <strong>艾尔利公司</strong> 的提醒：</p>
<ul>
<li>2026 年看起来 “必胜” 的 3 只生物科技股票</li>
</ul>
<p>其他几家机构投资者最近也对 LLY 的持仓进行了调整。住友三井金融集团在第二季度购买了艾尔利公司的新头寸，价值 27,000 美元。Evolution Wealth Management Inc. 在第二季度购买了艾尔利公司的新股份，价值约 29,000 美元。Steph &amp; Co. 在第三季度将其在艾尔利公司的股份增加了 290.0%。Steph &amp; Co. 现在拥有 39 股该公司的股票，价值 30,000 美元，此前在该期间又购买了 29 股。Financial Gravity Companies Inc. 在第二季度购买了艾尔利公司的新头寸，价值约 31,000 美元。最后，Bare Financial Services Inc 在第二季度将其在艾尔利公司的持股增加了 263.6%。Bare Financial Services Inc 现在拥有 40 股该公司的股票，价值 31,000 美元，此前在该期间又购买了 29 股。82.53% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>艾尔利公司的价格表现</h2>
<p>NYSE LLY 的股票周二开盘价为 1,063.34 美元。该公司的 50 日简单移动平均线为 1,057.99 美元，200 日简单移动平均线为 883.36 美元。公司的速动比率为 1.24，流动比率为 1.55，债务股本比率为 1.71。该公司的市值为 1.01 万亿美元，市盈率为 52.02，市盈增长比率为 0.80，贝塔值为 0.35。艾尔利公司的 52 周低点为 623.78 美元，52 周高点为 1,133.95 美元。</p>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
<p>艾尔利公司（NYSE:LLY - 获取免费报告）最后一次公布季度财报是在 10 月 30 日星期四。该公司报告每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超出 0.60 美元。该公司在该季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。艾尔利公司的净利润率为 30.99%，股本回报率为 109.52%。与去年同期相比，艾尔利公司的收入增长了 53.9%。去年同期，该公司每股收益为 1.18 美元。艾尔利公司已将 2025 财年的指导目标设定为 23.000-23.700 的每股收益。平均而言，股票分析师预测艾尔利公司在当前财年将发布 23.48 的每股收益。</p>
<h2>艾尔利公司增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 10 日星期二支付。记录在案的投资者将在 2 月 13 日星期五获得 1.73 美元的股息。这比艾尔利公司之前的季度股息 1.50 美元有所增加。这代表着每年 6.92 美元的股息和 0.7% 的股息收益率。该股息的除息日期为 2 月 13 日星期五。艾尔利公司的派息比率为 29.35%。</p>
<h2>更多艾尔利公司的新闻</h2>
<ul>
<li>一只长期投资者不应忽视的新 IPO</li>
</ul>
<p>以下是本周影响艾尔利公司的主要新闻故事：</p>
<ul>
<li>积极情绪：围绕 “体重污名” 的新营销推动旨在保护 Lilly 的肥胖药物品牌定位，随着竞争加剧；如果有效，可能有助于需求/市场份额。Eli Lilly（LLY）新营销聚焦于 “体重污名”</li>
<li>积极情绪：Guggenheim 将其目标价下调至$1,161，但重申买入评级——表明分析师仍然看到上涨空间，尽管预期有所减弱。Guggenheim 将 Eli Lilly and Company（LLY）的目标价下调至$1,161，重申 “买入” 评级</li>
<li>中性情绪：比较特征评估 Lilly 与同行（如 Viking、Novo Nordisk），使 LLY 保持在投资者讨论中，但不会立即改变基本面。Eli Lilly 或 Viking Therapeutics：哪只股票更有可能成为百万富翁制造者？</li>
<li>中性情绪：小型机构减持：Commerzbank 在其最新文件中披露了一笔小额出售（741 股）——单独来看并不重要，但属于常规投资组合调整。Eli Lilly and Company $LLY 股票被 Commerzbank Aktiengesellschaft FI 出售</li>
<li>消极情绪：主要医院贸易组织（AHA）和其他医院利益相关者正在敦促卫生资源与服务管理局阻止 Lilly 扩展的 340B 索赔数据提交政策——可能导致监管干预、医院关系中断和报销争议。AHA 敦促 HRSA 阻止 Eli Lilly 的 340B 索赔数据提交政策生效</li>
<li>消极情绪：媒体报道（STAT）强调医院呼吁政府阻止 Lilly 的 340B 政策——加大声誉和运营风险，并增加对覆盖实体药物获取的短期不确定性。医院团体希望特朗普政府阻止 Lilly 关于 340B 索赔数据的新政策</li>
<li>消极情绪：Lilly 自身扩展 340B 报告要求遭到医院的反对——该公司的透明度行动可能引发合同、定价或获取争议。Eli Lilly 将扩展 340B 报告要求</li>
<li>消极情绪：分析认为 Novo Nordisk 可能在与 Lilly 的竞争中重新获得优势，突显了减肥/糖尿病市场竞争的加剧——对定价和市场份额的长期压力。Novo Nordisk 与 Eli Lilly：形势可能正在转变</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师对该公司发表了评论。Weiss Ratings 在 12 月 22 日的报告中重新发布了 Eli Lilly and Company 的 “买入（b-）” 评级。摩根士丹利在 11 月 24 日的研究报告中将 Eli Lilly and Company 的目标价从$1,171.00 提高至$1,290.00，并给予该公司 “超配” 评级。Erste Group Bank 在 10 月 14 日的报告中将 Eli Lilly and Company 的评级从 “持有” 上调至 “买入”。Sanford C. Bernstein 在 12 月 19 日的报告中重申了 Eli Lilly and Company 的 “跑赢大盘” 评级。最后，Scotiabank 在 11 月 13 日的研究报告中开始覆盖 Eli Lilly and Company 的股票。他们给予该股 “行业跑赢大盘” 评级，并设定目标价为$1,165.00。四位股票研究分析师给予该股 “强烈买入” 评级，十八位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com，该公司目前的平均评级为 “买入”，共识目标价为$1,174.61。</p>
<p><strong>查看我们最新的 LLY 股票分析</strong></p>
<h2>关于 Eli Lilly and Company</h2>
<p>（免费报告）</p>
<p>Eli Lilly and Company NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。Eli Lilly 在北美、欧洲、亚洲及其他地区开展业务和商业活动，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 Eli Lilly and Company</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>如果您在美国银行账户中存放现金……请立即阅读</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资$1,000 于 Eli Lilly and Company 吗？</h2>
<p>在您考虑 Eli Lilly and Company 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Eli Lilly and Company 并不在名单上。</p>
<p>虽然 Eli Lilly and Company 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Belpointe Asset Management LLC 在第三季度减少了对礼来公司（NYSE: LLY）17.0% 的持股，目前持有 4,707 股，价值 3,592,000 美元。其他机构投资者也调整了他们的持仓。礼来的股票开盘价为 1,063.34 美元，市值为 1.01 万亿美元。该公司报告第三季度每股收益为 7.02 美元，超出预期，并宣布每股派息增加至 1.73 美元。分析师预测 2025 财年的每股收益为 23.48 美元，Guggenheim 维持 “买入” 评级，尽管将目标价格下调至 1,161 美元</p>

<p>Belpointe Asset Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 17.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,707 shares of the company's stock after selling 964 shares during the period. Belpointe Asset Management LLC's holdings in Eli Lilly and Company were worth $3,592,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Belpointe Asset Management LLC 在最近向证券交易委员会提交的文件中表示，在第三季度减少了对艾尔利公司（NYSE:LLY - 免费报告）17.0% 的持股。这家机构投资者在该期间出售了 964 股后，持有该公司 4,707 股股票。Belpointe Asset Management LLC 在艾尔利公司的持股在最近一个季度末价值为 3,592,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>艾尔利公司</strong> 的提醒：</p>
</div><ul>
<li>3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年看起来 “必胜” 的 3 只生物科技股票</li>
</ul>
</div><p>Several other institutional investors have also recently made changes to their positions in LLY. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph &amp; Co. grew its position in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock valued at $30,000 after acquiring an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc raised its holdings in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company's stock worth $31,000 after purchasing an additional 29 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也对 LLY 的持仓进行了调整。住友三井金融集团在第二季度购买了艾尔利公司的新头寸，价值 27,000 美元。Evolution Wealth Management Inc. 在第二季度购买了艾尔利公司的新股份，价值约 29,000 美元。Steph &amp; Co. 在第三季度将其在艾尔利公司的股份增加了 290.0%。Steph &amp; Co. 现在拥有 39 股该公司的股票，价值 30,000 美元，此前在该期间又购买了 29 股。Financial Gravity Companies Inc. 在第二季度购买了艾尔利公司的新头寸，价值约 31,000 美元。最后，Bare Financial Services Inc 在第二季度将其在艾尔利公司的持股增加了 263.6%。Bare Financial Services Inc 现在拥有 40 股该公司的股票，价值 31,000 美元，此前在该期间又购买了 29 股。82.53% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>艾尔利公司的价格表现</h2>
</div><p>Shares of NYSE LLY opened at $1,063.34 on Tuesday. The firm has a 50-day simple moving average of $1,057.99 and a 200-day simple moving average of $883.36. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.02, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.</p>
<div class="lb-trans"><p>NYSE LLY 的股票周二开盘价为 1,063.34 美元。该公司的 50 日简单移动平均线为 1,057.99 美元，200 日简单移动平均线为 883.36 美元。公司的速动比率为 1.24，流动比率为 1.55，债务股本比率为 1.71。该公司的市值为 1.01 万亿美元，市盈率为 52.02，市盈增长比率为 0.80，贝塔值为 0.35。艾尔利公司的 52 周低点为 623.78 美元，52 周高点为 1,133.95 美元。</p>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company's revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾尔利公司（NYSE:LLY - 获取免费报告）最后一次公布季度财报是在 10 月 30 日星期四。该公司报告每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超出 0.60 美元。该公司在该季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。艾尔利公司的净利润率为 30.99%，股本回报率为 109.52%。与去年同期相比，艾尔利公司的收入增长了 53.9%。去年同期，该公司每股收益为 1.18 美元。艾尔利公司已将 2025 财年的指导目标设定为 23.000-23.700 的每股收益。平均而言，股票分析师预测艾尔利公司在当前财年将发布 23.48 的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>艾尔利公司增加股息</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company's payout ratio is 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 10 日星期二支付。记录在案的投资者将在 2 月 13 日星期五获得 1.73 美元的股息。这比艾尔利公司之前的季度股息 1.50 美元有所增加。这代表着每年 6.92 美元的股息和 0.7% 的股息收益率。该股息的除息日期为 2 月 13 日星期五。艾尔利公司的派息比率为 29.35%。</p>
</div><h2>More Eli Lilly and Company News</h2>
<div class="lb-trans"><h2>更多艾尔利公司的新闻</h2>
</div><ul>
<li>A Fresh IPO That Long-Term Investors Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>一只长期投资者不应忽视的新 IPO</li>
</ul>
</div><p>Here are the key news stories impacting Eli Lilly and Company this week:</p>
<div class="lb-trans"><p>以下是本周影响艾尔利公司的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: New marketing push around “weight stigma” aims to protect brand positioning for Lilly’s obesity medicines as competition heats up; could help demand/market share if effective. Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’</li>
<li>Positive Sentiment: Guggenheim cut its price target to $1,161 but reiterated a Buy rating — indicates analysts still see upside, though expectations have been tempered. Guggenheim reduces PT on Eli Lilly and Company (LLY) to $1,161, reiterates 'Buy' rating</li>
<li>Neutral Sentiment: Comparative features evaluating Lilly vs. peers (e.g., Viking, Novo Nordisk) keep LLY in investor conversations but don’t change fundamentals immediately. Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?</li>
<li>Neutral Sentiment: Small institutional trimming: Commerzbank disclosed a minor sale (741 shares) in its latest filings — not material alone but part of regular portfolio moves. Eli Lilly and Company $LLY Shares Sold by Commerzbank Aktiengesellschaft FI</li>
<li>Negative Sentiment: Major hospital trade group (AHA) and other hospital stakeholders are urging the Health Resources &amp; Services Administration to block Lilly’s expanded 340B claims-data submission policy — potential for regulatory intervention, disrupted hospital relationships, and reimbursement disputes. AHA urges HRSA to stop Eli Lilly’s 340B claims-data submission policy from going into effect</li>
<li>Negative Sentiment: Press coverage (STAT) highlights hospital calls for the administration to block Lilly’s 340B policy — amplifies reputational and operational risk and increases near-term uncertainty around drug access for covered entities. Hospital group wants Trump administration to block a new Lilly policy on 340B claims data</li>
<li>Negative Sentiment: Lilly’s own expansion of 340B reporting requirements is drawing pushback from hospitals — the company action intended for transparency could trigger contractual, pricing or access disputes. Eli Lilly to expand 340B reporting requirements</li>
<li>Negative Sentiment: Analysis arguing Novo Nordisk may be regaining ground vs. Lilly highlights intensifying competition in weight-loss/diabetes markets — a longer-term pressure on pricing and market share. Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：围绕 “体重污名” 的新营销推动旨在保护 Lilly 的肥胖药物品牌定位，随着竞争加剧；如果有效，可能有助于需求/市场份额。Eli Lilly（LLY）新营销聚焦于 “体重污名”</li>
<li>积极情绪：Guggenheim 将其目标价下调至$1,161，但重申买入评级——表明分析师仍然看到上涨空间，尽管预期有所减弱。Guggenheim 将 Eli Lilly and Company（LLY）的目标价下调至$1,161，重申 “买入” 评级</li>
<li>中性情绪：比较特征评估 Lilly 与同行（如 Viking、Novo Nordisk），使 LLY 保持在投资者讨论中，但不会立即改变基本面。Eli Lilly 或 Viking Therapeutics：哪只股票更有可能成为百万富翁制造者？</li>
<li>中性情绪：小型机构减持：Commerzbank 在其最新文件中披露了一笔小额出售（741 股）——单独来看并不重要，但属于常规投资组合调整。Eli Lilly and Company $LLY 股票被 Commerzbank Aktiengesellschaft FI 出售</li>
<li>消极情绪：主要医院贸易组织（AHA）和其他医院利益相关者正在敦促卫生资源与服务管理局阻止 Lilly 扩展的 340B 索赔数据提交政策——可能导致监管干预、医院关系中断和报销争议。AHA 敦促 HRSA 阻止 Eli Lilly 的 340B 索赔数据提交政策生效</li>
<li>消极情绪：媒体报道（STAT）强调医院呼吁政府阻止 Lilly 的 340B 政策——加大声誉和运营风险，并增加对覆盖实体药物获取的短期不确定性。医院团体希望特朗普政府阻止 Lilly 关于 340B 索赔数据的新政策</li>
<li>消极情绪：Lilly 自身扩展 340B 报告要求遭到医院的反对——该公司的透明度行动可能引发合同、定价或获取争议。Eli Lilly 将扩展 340B 报告要求</li>
<li>消极情绪：分析认为 Novo Nordisk 可能在与 Lilly 的竞争中重新获得优势，突显了减肥/糖尿病市场竞争的加剧——对定价和市场份额的长期压力。Novo Nordisk 与 Eli Lilly：形势可能正在转变</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have commented on the company. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Morgan Stanley increased their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, November 24th. Erste Group Bank raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, October 14th. Sanford C. Bernstein reaffirmed an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Finally, Scotiabank initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $1,165.00 target price on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and a consensus target price of $1,174.61.</p>
<div class="lb-trans"><p>几位分析师对该公司发表了评论。Weiss Ratings 在 12 月 22 日的报告中重新发布了 Eli Lilly and Company 的 “买入（b-）” 评级。摩根士丹利在 11 月 24 日的研究报告中将 Eli Lilly and Company 的目标价从$1,171.00 提高至$1,290.00，并给予该公司 “超配” 评级。Erste Group Bank 在 10 月 14 日的报告中将 Eli Lilly and Company 的评级从 “持有” 上调至 “买入”。Sanford C. Bernstein 在 12 月 19 日的报告中重申了 Eli Lilly and Company 的 “跑赢大盘” 评级。最后，Scotiabank 在 11 月 13 日的研究报告中开始覆盖 Eli Lilly and Company 的股票。他们给予该股 “行业跑赢大盘” 评级，并设定目标价为$1,165.00。四位股票研究分析师给予该股 “强烈买入” 评级，十八位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com，该公司目前的平均评级为 “买入”，共识目标价为$1,174.61。</p>
</div><p><strong>View Our Latest Stock Analysis on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LLY 股票分析</strong></p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于 Eli Lilly and Company</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>Eli Lilly and Company NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。Eli Lilly 在北美、欧洲、亚洲及其他地区开展业务和商业活动，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Eli Lilly and Company</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>如果您在美国银行账户中存放现金……请立即阅读</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资$1,000 于 Eli Lilly and Company 吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Eli Lilly and Company 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Eli Lilly and Company 并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eli Lilly and Company 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Eli Lilly and Company $LLY Shares Sold by Belpointe Asset Management LLC

Market Beat

标普生物技术 3 倍做空 - Direxion

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - Vanguard

基因改革 ETF - ARK

Invesco Nasdaq Biotechnology ETF

标普生物技术 ETF - SPDR

华夏医药ETF

2 倍做空纳斯达克生物技术 ETF - ProShares

1 倍做空 LLY ETF - Direxion

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

2 倍做多 LLY ETF - Defiance

医疗业 ETF - SPDR

礼来公司 $LLY 的股票被 Belpointe 资产管理有限责任公司出售